---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-25-000073"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:11:58.185659+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma Q3 rev $1.13B (+7%), GAAP EPS $4.08, adj. EPS $8.13; FY25 rev guid narrowed

## Summary
- Total revenues $1.126B (+7% YoY); GAAP net income $251M, non-GAAP adj. net income $501M.
- Epidiolex sales grew 20% to $302.6M; Xywav sales grew 11% to $431.4M; Modeyso launch contributed $11.0M.
- Zepzelca + atezolizumab combo approved for 1L maintenance ES-SCLC; NCCN inclusion.
- Saniona licensing agreement for SAN2355, a Kv7.2/7.3 activator for epilepsy and other indications.
- FY2025 total revenue guidance narrowed to $4.175-$4.275B from $4.150-$4.300B.

## SEC filing metadata
- accession: 0001232524-25-000073
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/0001232524-25-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/jazz-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-25-000073
- JSON: https://secwatch.observer/filing/0001232524-25-000073.json
- Plain text: https://secwatch.observer/filing/0001232524-25-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.